Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus

Öztürk, Derya; Çelik, Ömer; Satılmış, Seçkin; Aslan, Serkan; Ertürk, Mehmet; Çakmak, Hüseyin Altuğ; Kalkan, Ali Kemal; Ozyilmaz, Sinem Ozbey; Diker, Vesile Ornek; Gül, Mehmet

doi:10.1097/mca.0000000000000252

Cited by 43 publications

(41 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Galectin-3 levels were correlated with BMI, hs-CRP, and the total number of plaques. Older age, smoking, high hs-CRP, and high LDL-cholesterol concentrations, in addition to galectin-3, were predictors of coronary atherosclerosis in patients with type 2 DM [10]. In our study, consistent with the findings of this study, BMI, hs-CRP, and the total number of plaques were significantly positively correlated with galectin-3.…”

Section: Discussionsupporting

confidence: 82%

“…Moreover, de Boer et al [9] reported that galectin-3 level was an independent predictor of all-cause and cardiovascular mortality in the general population, independent of other cardiovascular risk factors. A significant relationship between serum galectin-3 concentrations and the total number of coronary plaques and the macrocalcified plaque structures, as detected by CCTA, of patients with type 2 DM was demonstrated in a study by Ozturk et al [10]. Galectin-3 levels were correlated with BMI, hs-CRP, and the total number of plaques.…”

Section: Discussionmentioning

confidence: 92%

“…Ozturk et al [10] reported a significant relationship between serum galectin-3 concentrations and the total number of coronary plaques and the macrocalcified plaque structures, as detected by coronary computed tomography angiography (CCTA), of patients with type 2 diabetes mellitus (DM).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Galectin-3 is associated with coronary plaque burden and obstructive sleep apnoea syndrome severity

Püşüroğlu

Somuncu

Bolat³

et al. 2017

Kardiol Pol

View full text Add to dashboard Cite

A b s t r a c tBackground: Obstructive sleep apnoea syndrome (OSAS) is reported to be associated with hypertension, coronary artery disease, atrial fibrillation, and heart failure. Galectin-3 plays an important role in the regulation of inflammation, development of cardiac fibrosis, and remodelling. A significant relationship between galectin-3 and the total number of coronary plaques and the macrocalcified plaque structures of patients with type 2 diabetes mellitus has been reported. Aim:The aim of this study was to investigate the association between galectin-3 level and coronary plaque burden as well as OSAS severity in patients with OSAS.Methods: A total of 87 consecutive patients with a diagnosis of OSAS and 21 age-and gender-matched control subjects were recruited for the present study. The patients with OSAS were also categorised according to their apnoea hypopnoea index (AHI) as follows: mild (AHI = 5-15), moderate (AHI = 15-30), and severe (AHI > 30). All study subjects underwent coronary computed tomography angiography to detect coronary atherosclerosis. Also, all participants of serum galectin-3 concentrations were measured.Results: Mean galectin-3 level was significantly higher in patients with OSAS compared to control subjects (p < 0.001) and in the severe OSAS group, compared to the moderate and mild OSAS groups (p < 0.001). Correlation analysis indicated significant positive relationships between galectin-3 concentrations and the total number of coronary plaques (p < 0.001), high-sensitivity C-reactive protein (p = 0.001), and severity of OSAS (p < 0.001). In multivariate analysis, galectin-3 (p = 0.01) and age (p = 0.025) were significant independent predictors of coronary atherosclerosis, after adjusting for other risk factors. Also, it has been found that galectin-3 concentration is a predictor of OSAS severity (p = 0.001).Conclusions: Galectin-3 is associated with coronary atherosclerosis and OSAS severity in OSAS patients.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Galectin-3 is associated with coronary plaque burden and obstructive sleep apnoea syndrome severity

Püşüroğlu

Somuncu

Bolat³

et al. 2017

Kardiol Pol

View full text Add to dashboard Cite

show abstract

“…72 In diabetic patients, galectin-3 concentrations were significantly elevated in subjects with coronary artery disease and associated with the formation of diseased vessels and plaques. 74 Darrow et al found that mice developed hyperglycemia since week 2 of high-fat diet feeding, which was indicated by a threefold increase in homeostasis model assessment for insulin resistance (HOMA-IR) index and a 1.5-fold decrease in Akt activation. The authors also found increased galectin-3 expression in endothelial cells as well as circulating galectin-3 in high-fat diet-fed mice, suggesting that galectin-3 plays a role in the vascular response in DM (Table 1).…”

Section: Galectin-3 In Metabolic Disease Pathogenesismentioning

confidence: 99%

“…In clinical studies, circulating galectin-3 was higher in type 2 DM patients [71][72][73][74] and thought to be a risk factor for vascular complications, such as heart failure, nephropathy, peripheral artery disease, and other vascular complications. 71 Patients with galectin-3 level 25 ng/mL exhibited a 11.4-fold higher risk of microvascular complications (retinopathy and/or nephropathy) and a 8.5-fold increased risk of macrovascular complications (myocardial infraction, angina pectoris, cerebrovascular event, and peripheral artery disease) compared to patients with galectin-3 level 10 ng/mL.…”

Section: Galectin-3 In Metabolic Disease Pathogenesismentioning

confidence: 99%

Galectin-3 and Inflammation

Wan

Liu

2016

Glycobiology Insights

View full text Add to dashboard Cite

ABSTRACT:Galectins are a family of β-galactoside-binding proteins that share a consensus sequence in the carbohydrate recognition domain (CRD). Galectin-3 is the most widely studied family member and can be found in the cellular cytoplasm and nucleus, as well as extracellularly in various tissues. The 30-kDa molecule contains an N-terminal proline-rich domain that is important for its oligomerization and a C-terminal CRD for carbohydrate-binding activity. Many studies have shown that galectin-3 may regulate inflammation through a variety of mechanisms. Endogenous galectin-3 has been shown to be involved in the pathogenesis of various diseases, such as fibrosis in the lung, liver, and heart, diabetes mellitus, coronary artery disease, and allergic diseases. In this review, we briefly discuss the pro-or anti-inflammatory roles, as well as potential clinical implications of galectin-3 in these disorders.

show abstract

Galectin‐3 and risk of cardiovascular events and all‐cause mortality in type 2 diabetes

Tan

Cheung

Lee

et al. 2018

Diabetes Metabolism Res

View full text Add to dashboard Cite

Aims Recent clinical studies have shown that galectin‐3 is a prognostic indicator in patients with coronary heart disease and in patients with heart failure. Experimental data suggest that galectin‐3 may play a role in atherogenesis. We have evaluated whether serum galectin‐3 level is associated with cardiovascular outcome in type 2 diabetes. Materials and methods Galectin‐3 was measured in baseline samples in 1495 persons with type 2 diabetes. The primary cardiovascular outcome, incident cardiovascular events, was defined as first non‐fatal myocardial infarction, non‐fatal stroke, coronary revascularization, or death from cardiovascular cause. The secondary outcome was all‐cause mortality. Results At baseline, 12% of the subjects had prevalent cardiovascular disease. Serum galectin‐3 was increased in the group with incident cardiovascular events compared with those who remained free of events during follow up (9.03 ± 2.98 ng/mL vs 8.15 ± 2.76, P < 0.01). Serum galectin‐3 was also significantly increased in those subjects with a fatal outcome. The hazard ratios (HR) for cardiovascular events and all‐cause mortality for individuals in the top quartile were 2.50 (95% CI 1.87, 3.36, P < 0.001) and 3.92 (95%CI 2.55, 6.01, P < 0.001), respectively. In a multivariate Cox regression analysis including traditional risk factors, log (eGFR), baseline albuminuria, and cardiovascular disease status, the HR per standard deviation change in galectin‐3 was 1.13 (95% CI 1.02, 1.26, P = 0.02) for cardiovascular events and 1.17 (95% CI 1.01, 1.35, P = 0.04) for all‐cause mortality. Conclusions Serum galectin‐3 is associated with adverse cardiovascular outcomes in persons with type 2 diabetes independent of traditional risk factors.

show abstract

Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus

Abstract: Galectin-3 is a novel, promising biomarker that may help identify type 2 diabetic patients who may require early CAD intervention because of the potential risk of coronary atherosclerosis.

Cited by 43 publications

References 23 publications

Galectin-3 is associated with coronary plaque burden and obstructive sleep apnoea syndrome severity

Galectin-3 is associated with coronary plaque burden and obstructive sleep apnoea syndrome severity

Galectin-3 and Inflammation

Galectin‐3 and risk of cardiovascular events and all‐cause mortality in type 2 diabetes

Contact Info

Product

Resources

About